Latest News

Audentes Therapeutics Announces Plans to Build New State-of-the-Art Gene Therapy Manufacturing Facility in Sanford, North Carolina

SAN FRANCISCO & RALEIGH, N.C.–(BUSINESS WIRE)–Audentes Therapeutics, an Astellas company focused on developing innovative AAV-based genetic medicines, announced today that it plans to invest $109 million to build a new 135,000 square foot, state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina. The initial phase of the capital investment is planned to occur over approximately 18 months, and the plant is expected to be operational in 2021. The remaining investment will

Source link

Related posts

AHF Urges WHO to Immediately Declare Novel Coronavirus an International Health Emergency


Medical News Today: Music may enhance the effect of pain relievers


Quell Non-Medication Solution for Chronic Pain: Interview with CEO Shai Gozani


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy